Prevalencia del dolor neuropático (DN), según DN4, en atención primaria

Blanco, Eric; Gálvez, R.; Zamorano, Ernesto Reyes; López, Vicente Sanjosé; Pérez, M.

doi:10.1016/j.semerg.2011.10.012

Cited by 8 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients from a previous NP prevalence study [23] were followed up for 3 months to assess the progression of pain-related parameters and treatment satisfaction. This publication is a post hoc analysis performed in patients from the previous NP prevalence study treated with pregabalin [23] who had not been exposed to the drug in the previous 3 months.…”

Section: Methodsmentioning

confidence: 99%

“…This publication is a post hoc analysis performed in patients from the previous NP prevalence study treated with pregabalin [23] who had not been exposed to the drug in the previous 3 months. The study protocol was approved by the Clinical Research Ethics Committee of Virgen de las Nieves Hospital (Granada, Spain) in 2008 and complied with all ethical considerations involving human subjects in accordance with the Declaration of Helsinki, and followed standard security and confidentiality measures in compliance with Spanish legislation.…”

Section: Methodsmentioning

confidence: 99%

“…In a previous cross-sectional study conducted in a Spanish primary care setting, NP prevalence according to the Douleur Neuropathique en 4 questions (DN4) was 45.7 % in patients with pain visiting primary care centers [23]. These NP patients experienced moderate pain and high levels of pain interference with their activities of daily living and showed little satisfaction with treatment.…”

Section: Introductionmentioning

confidence: 99%

“…Specifically, in the Spanish primary care setting, pregabalin was shown to be an effective therapy for the treatment of peripheral NP in patients refractory to at least one previous analgesic in routine clinical practice [43, 44]. Therefore, from the previous cross-sectional study [23], of all the patients followed for 3 months, this publication focuses on those who were treated with pregabalin to confirm the beneficial effect of this treatment, with the aim of improving the management of NP. This publication presents original data as it is a naturalistic study of a large number of patients in the primary care environment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting

Tarrío¹,

Mateos

Bayarri³

et al. 2013

Clin Drug Investig

View full text Add to dashboard Cite

Background and ObjectivePatients from a previous study of neuropathic pain (NP) in the Spanish primary care setting still had symptoms despite treatment. Subsequently, patients were treated as prescribed by their physician and followed up for 3 months. Since pregabalin has been shown to be effective in NP, including refractory cases, the objective of this study was to assess the effectiveness of pregabalin therapy in patients with NP refractory to previous treatments.MethodsThis was a post hoc analysis of pregabalin-naïve NP patients treated with pregabalin in a 3-month follow-up observational multicenter study to assess symptoms and satisfaction with treatment. Patients were evaluated with the Douleur Neuropathique en 4 questions (DN4), the Brief Pain Inventory (BPI) and the Treatment Satisfaction for Medication Questionnaire (SATMED-Q) overall satisfaction domain.Results1,670 patients (mean age 58 years, 59 % women), previously untreated or treated with ≥1 drug other than pregabalin, were treated with pregabalin (37 % on monotherapy). At 3 months, pain intensity and its interference with activities decreased by half (p < 0.0001), while the number of days with no or mild pain increased by a mean of 4.5 days (p < 0.0001). Treatment satisfaction increased twofold (p < 0.0001). Patients with a shorter history of pain and those with neuralgia and peripheral nerve compression syndrome (PCS) as etiologies had the highest proportion on monotherapy and showed the greatest improvements in pain-related parameters in their respective group categories.ConclusionTreatment with pregabalin (as monotherapy or combination therapy) provides benefits in pain and treatment satisfaction in patients with NP, including refractory cases. Shorter disease progression and neuralgia and PCS etiologies are favorable factors for pregabalin treatment response.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting

Tarrío¹,

Mateos

Bayarri³

et al. 2013

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

“…10 Some studies performed by Spanish general practitioners showed that neuropathic pain may also be present in a significant percentage of subjects seen for chronic pain in outpatient clinics. 11 The peculiarity of our study was to evaluate patients affected by chronic pain in internal medicine wards. In these wards the percentage of patients suffering from cancer chronic pain is not all-encompassing.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of neuropathic component of pain in a cohort of patients admitted to an Internal Medicine Department for chronic pain

Chesi¹,

Scanelli

Gilioli³

et al. 2015

Ital J Med

View full text Add to dashboard Cite

Due to the increasing age of the population the number of people suffering from chronic pain has significantly increased. People with chronic pain suffer from various diseases. Often this pain is not adequately controlled and is refractory, while its neuropathic component, which requires a different treatment, is perhaps underestimated compared to more properly nociceptive pain. The purpose of this study was to evaluate the presence of a neuropathic component in a cohort of 105 patients consecutively admitted to three Internal Medicine Units in Emilia Romagna. For the identification of the component of neuropathic pain diagnostic (DN4) questionnaire, previously validated, has been used. The average age of the patients studied was 64.4 years. The group of subjects with chronic non-cancer pain (78%) was numerically higher than the group of patients suffering from cancer pain (22%). All patients had pain and, according to the visual analogue scale (VAS), pain ranged from moderate to severe (median 7). Although without reaching statistically significant data, according to the VAS scale, cancer pain had an average higher value than non-cancer pain (7 vs 6.5). The prevalence of neuropathic component of pain was higher in patients with non-cancer pain (66% vs 57%). Instead, the recorded pain intensity in patients with neuropathic component was statistically much higher than the group in which the neuropathic component was absent (6.9 vs 6.1; P<0.05). In patients suffering from chronic pain, regardless of its nature and its etiology, the presence of a neuropathic component is significant. We must become aware of it and must search for it regularly through appropriate tools, such as the DN4 questionnaire. The presence of a neuropathic component usually makes the pain more intense and more refractory to treatments commonly used. Search for it may have therapeutic implications, suggesting that doctors use drugs active on this component. Since the majority of patients suffering from chronic pain are admitted to internal medicine wards, this awareness ought to become cultural heritage for the internist.Correspondence: Giuseppe Chesi, viale Martiri della Libertà 2,

show abstract

La salud mental determina la calidad de vida de los pacientes con dolor neuropático oncológico en Quito, Ecuador

Altamirano

Torres

Salas

et al. 2017

Revista Colombiana de Psiquiatría

View full text Add to dashboard Cite

Prevalencia del dolor neuropático (DN), según DN4, en atención primaria

Cited by 8 publications

References 24 publications

Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting

Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting

Prevalence of neuropathic component of pain in a cohort of patients admitted to an Internal Medicine Department for chronic pain

La salud mental determina la calidad de vida de los pacientes con dolor neuropático oncológico en Quito, Ecuador

Contact Info

Product

Resources

About